Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. Its lead program, NKX019, is a CAR NK product candidate targeting CD19 for autoimmune diseases including lupus nephritis, systemic sclerosis, myositis, and ANCA-associated vasculitis. NKX019 is being studied in Phase 1 trials (Ntrust-1, Ntrust-2) and investigator-sponsored trials. The company operates cGMP manufacturing facilities in South San Francisco, California.
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001787400-26-000006 | EDGAR | 89K words |
| 2025-03-26 | 2024-12-31 | 0000950170-25-045262 | EDGAR | 87K words |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034735 | EDGAR | 92K words |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008523 | EDGAR | 85K words |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004095 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015517 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001787400-26-000017 | EDGAR | 64K words |
| 2025-11-10 | 2025-09-30 | 0001193125-25-274304 | EDGAR | 64K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178964 | EDGAR | 62K words |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071455 | EDGAR | 60K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123395 | EDGAR | 62K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096186 | EDGAR | 62K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056980 | EDGAR | 61K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062091 | EDGAR | 60K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040953 | EDGAR | 59K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021277 | EDGAR | 56K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023845 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016892 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-342402 | EDGAR | 2K words |
| 2026-03-26 | 0001787400-26-000008 | EDGAR | 1K words |
| 2026-03-25 | 0001787400-26-000005 | EDGAR | 2K words |
| 2025-11-10 | 0001193125-25-274261 | EDGAR | 2K words |
| 2025-08-12 | 0001193125-25-178949 | EDGAR | 2K words |
| 2025-06-06 | 0000950170-25-082717 | EDGAR | 1K words |
| 2025-05-14 | 0000950170-25-071399 | EDGAR | 2K words |
| 2025-03-26 | 0000950170-25-045231 | EDGAR | 3K words |
| 2024-11-07 | 0000950170-24-123340 | EDGAR | 2K words |
| 2024-08-13 | 0000950170-24-096163 | EDGAR | 2K words |
101 total filings indexed. 73 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001787400 |
| Ticker | NKTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | South San Francisco, California |
| Website | https://www.nkartatx.com |
| Listed | 2020-07-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NKTX (~200 tokens, structured JSON with cryptographic provenance)